Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer

Journal of Clinical Oncology

Volumn 18, Issue 6, 2000, Pages 1164-1172

  D'Amico, Anthony V ^a   Whittington, Richard ^a   Malkowicz, S Bruce ^a   Schultz, Delray ^a   Fondurulia, Julia ^a   Chen, Ming Hui ^a   Tomaszewski, John E ^a   Renshaw, Andrew A ^a   Wein, Alan ^a   Richie, Jerome P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CANCER SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034104315     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.6.1164     Document Type: Article

References (45)

1. Partin AW, Kattan MW, Subong ENP, et al: Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: A multi-institutional update. JAMA 277:1445-1452, 1997
2. D'Amico AV, Whittington R, Malkowicz SB, et al: Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: The basis for an adjuvant therapy trial. J Clin Oncol 15:1465-1469, 1997
3. Lerner SE, Blute ML, Bergstralh EJ, et al: Analysis of risk factors for progression in patients with pathologically organ confined prostate cancers after radical retropubic prostatectomy. J Urol 156:137-143, 1996
4. Kupelian P, Katcher J, Levin HS, et al: Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 37:1043-1052, 1997
5. D'Amico AV, Whittington R, Kaplan I, et al: Equivalent biochemical failure free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. Int J Radiat Oncol Biol Phys 37:1053-1058, 1997
6. Kattan MW, Easthan JA, Stapleton AMF, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766-771, 1998
7. D'Amico AV, Whittington R, Broderick GA, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
8. Terris MK, Haney DJ, Johnstone IM, et al: Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology 45:75-80, 1995
9. Borirakchanyavat S, Bhargava V, Shinohara K, et al: Systematic sextant biopsies in the prediction of extracapsular extension at radical prostatectomy. Urology 50:373-378, 1997
10. Badalment RA, Miller MC, Peller PA, et al: An algorithm for predicting non-organ confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 156:1375-1380, 1996
11. D'Amico AV, Whittington R, Malkowicz SB, et al: Role of percent positive biopsies and endorectal coil MRI in predicting prognosis in intermediate-risk prostate cancer patients. Cancer J Sci Am 2:343-350, 1996
12. Conrad S, Graefen M, Pichlmeier, et al: Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostate carcinoma. J Urol 159:2023-2029, 1998
13. Epstein JI, Walsh PC, Carmichael M, et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368-374, 1994
14. Gleason DF: Histologic grading and staging of prostatic carcinoma, in Tannenbaum M (ed): Urologic Pathology. Philadelphia, PA, Lea & Febiger, 1977, pp 171-187
15. Beahrs OH, Henson DE, Hutter RVP: American Joint Committee on Cancer Manual for Staging Cancer (ed 4). Philadelphia, PA, JB Lippincott, 1992
16. Oesterling JE, Jacobsen SJ, Klee GG, et al: Free, complexed and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154:1090-1095, 1995
17. Epstein JI, Pizov G, Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71:3582-3589, 1993
18. Neter J: Simultaneous inferences and other topics in regression analysis-1, in Neter J, Wasserman W, Kutner M (eds): Applied Linear Regression Models (ed 1). Homewood, IL, Richard D. Irwin, Inc. 1983, pp 150-153
19. Efron R, Tibsherani R: An Introduction to the Bootstrap. New York, NY, Chapman and Hall, 1993
20. Schemper M: The relative importance of prognostic factors in studies of survival. Stat Med 12:2377-2402, 1993
21. Armitage P: Test for linear trend in proportions and frequencies. Biometrics 11:375-384, 1955
22. Zagars GK, Pollack A, Kavadi VS, et al: Prostate specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32:293-306, 1995
23. Pisansky TM, Kahn MJ, Rasp GM, et al: A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate cancer. Cancer 79:337-344, 1997
24. Lee WR, Hanks GE, Schultheiss TE, et al: Localized prostate cancer treated by external beam radiotherapy alone: Serum prostate-specific antigen-driven outcome analysis. J Clin Oncol 13:464-469, 1995
25. Pisansky TM, Cha SS, Earle JD, et al: Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 11:2158-2166, 1993
26. Zietman AL, Coen JJ, Shipley WU, et al: Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J Urol 151:640-645, 1994
27. Hanks GE, Lee WR, Schultheiss TE: Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 154:456-459, 1995
28. Partin AW, Piantadosi S, Sanda MG, et al: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 45:831-838, 1995
29. Zietman AL, Edelstein RA, Coen JJ, et al: Radical prostatectomy for adenocarcinoma of the prostate: The influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 43:828-833, 1994
30. D'Amico AV, Whittington R, Malkowicz SB, et al: Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol 158:1422-1426, 1997
31. Ragde H, Blasko JC, Grimm PD, et al: Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 80:442-453, 1997
32. Blasko JC, Wallner K, Grimm PD, et al: Prostate specific antigen based disease control following ultrasound guided I 125 implantation for stage T1/T2 prostatic carcinoma. J Urol 154:1096-1099, 1995
33. Wallner K, Roy J, Harrison L: Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 14:449-453, 1996
34. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
35. Ismail MT, Petersen RO, Alexander AA, et al: Tumor vascularity assessed by color Doppler imaging in prostate cancer: Prognostic implications. J Urol 159:288, 1998 (abstr 1110)
36. D'Amico AV, Whittington R, Tomaszewski JE, et al: Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. J Clin Oncol 14:1770-1777, 1996
37. Yang RM, Naitoh J, Murphy M, et al: Low P27 Expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159:941-945, 1998
38. Stapleton AM, Zbell P, Kattan MW, et al: Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 82:168-174, 1998
39. Waltregny D, de Leval L, Menard S, et al: Independent prognostic value of the 67-kd laminin receptor in human prostate cancer. J Natl Cancer Inst 89:1224-1228, 1997
40. Theodorescu D, Broder SR, Boyd JC, et al: Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 80:2109-2112, 1997
41. Snow PB, Levine RF, Ziada AM, et al: Impact of different variables on outcome of treatments for clinically confined prostate cancer: Prediction of response and pathological stage of the disease using a neural network. J Urol 159:295, 1998 (abstr 1136)
42. Presti JC Jr, Shinohara K, Bacchetti P, et al: Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology 52:1079-1084, 1998
43. Vashi AR, Wojno KJ, Gillespie B, et al: A model for the number of core per prostate biopsy based on patient age and prostate gland volume. J Urol 159:920-924, 1998
44. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
45. Iselin CE, Robertson JE, Paulson DF: Radical perineal prostatectomy: Oncological outcome during a 20-year period. J Urol 161: 163-168, 1999